{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:32:58Z","timestamp":1759332778299,"version":"3.37.3"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Thoracic radiotherapy administered concurrently with chemotherapy is the standard of care for patients with inoperable stage <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> non\u2010small cell lung cancer, but the optimal chemotherapy regimen is not clearly established. The objective of this study was to assess outcomes in a large cohort of patients treated with curative\u2010intent using carboplatin and paclitaxel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive patients undergoing curative\u2010intent radiotherapy to 60\u201366\u2009Gy in 30\u201333 daily fractions with concurrent weekly carboplatin (<jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\u2009=\u20092) and paclitaxel (45\u2009mg\/m<jats:sup>2<\/jats:sup>\/week) between <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>arch 2004 and <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ay 2012 were identified from a prospective database and reviewed individually. A minimum follow\u2010up of 3 months was required unless death occurred sooner. Response to treatment was defined according to established guidelines on re\u2010staging computed tomography scan at 3 months. Toxicities were assessed using a standardised scoring system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and seven patients were analysed. The median follow\u2010up was 43.5 months. Three months after treatment, a complete or partial response was observed in 72 patients (68%), and nine patients (8%) had already died. The overall locoregional failure rate was 47%, and failure eventually occurred at any site in 75 patients (70%). Median progression\u2010free survival, and median survival were 15 and 22 months, respectively. Grade 3\u20134 neutropaenia, thrombocytopaenia, nephrotoxicity, oesophagitis and pneumonitis were observed in 15%, 1%, 3%, 11% and 9% of patients during treatment, respectively. There was one episode of fatal radiation pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with thoracic radiotherapy and concurrent carboplatin and paclitaxel chemotherapy is feasible. Survival and toxicity outcomes compare favorably to those reported using cisplatin\u2010based regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/crj.12233","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T12:25:09Z","timestamp":1414585509000},"page":"428-434","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes treating stage <scp>III<\/scp> non\u2010small cell lung carcinoma with curative\u2010intent radiotherapy and concurrent carboplatin\u2010paclitaxel chemotherapy"],"prefix":"10.1111","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-2172","authenticated-orcid":false,"given":"Hon","family":"Trinh","sequence":"first","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Blayne","family":"Pinkham","sequence":"additional","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"},{"name":"University of Queensland  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Lehman","sequence":"additional","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"},{"name":"University of Queensland  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dannie","family":"Zarate","sequence":"additional","affiliation":[{"name":"Consultant, Statistics and Data Analysis  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Dauth","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Princess Alexandra Hospital  Woolloongabba Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"McGrath","sequence":"additional","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"McCaffrey","sequence":"additional","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang Tao","family":"Mai","sequence":"additional","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Horwood","sequence":"additional","affiliation":[{"name":"Cancer Care Services Princess Alexandra Hospital  Woolloongabba Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0084"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3210"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.405"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318268ff90"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.02.011"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3569"},{"issue":"2","key":"e_1_2_6_17_1","first-page":"S3","article-title":"An intergroup randomized phase III comparison of standard\u2010dose (60\u2009Gy) vs high\u2010dose (74\u2009Gy) chemoradiotherapy (CRT)\u2009+\/\u2212 cetuximab for stage III non\u2010small cell lung cancer (NSCLC): results from RTOG 0617","volume":"8","author":"Bradley J","year":"2013","journal-title":"J Thorac Oncol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.03.004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2001.n.023"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.n.016"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2011.10.005"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1580-y"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0728"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp008"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355107"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.442"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.04.043"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.091"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcrj.12233","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.12233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:42:22Z","timestamp":1696304542000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/crj.12233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/crj.12233"],"URL":"https:\/\/doi.org\/10.1111\/crj.12233","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"type":"print","value":"1752-6981"},{"type":"electronic","value":"1752-699X"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}